The popularity of decentralized clinical trials (DCTs) is surging, especially among patients. Harnessing technology of all kinds, these trials provide an attractive alternative to the old-style, site-anchored system on which traditional clinical trials have rested. They also have the potential to provide better, more timely data since that data is primarily collected under real-life situations and often available more quickly to monitoring teams, according to Kristin Mauri, Director of Solution Services, Remarque Systems.
According to a study released by Infogroup, a provider of data and data-driven intelligence solutions, four in five consumers say they are more concerned about privacy than they used to be – a tendency marketers ought to keep in mind.
It has long been thought that electronic data collection, also known as EDC, would be a time-saver when it comes to running clinical trials. But that may not be the case, according to a joint study released by Tufts University and Veeva Systems.
Marketers need to dig deeper to facilitate communications that are dynamic enough to reach and engage patients on a more personal, emotional level.
While data help manufacturers fix plant-floor problems and trace quality issues to their source, it also can prevent recalls. Why not proactively use data to attain an end-to-end view of operations so that product quality can be ensured while reducing recalls?
As biologic medications administered through prefilled syringes continue to supplement and enter new therapeutic areas, more and more patients will need to embark on a learning curve that is possibly unlike any they have experienced prior.